Coronavirus Disease 2019 (COVID-19)

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents
New Content ........................................................................................................................................... 3
Public Health Agencies .............................................................................................................................. 3
   Public Health Agency of Canada | canada.ca .......................................................................................... 3
   BC Centre for Disease Control | bccdc.ca .............................................................................................. 3
   Institut national de santé publique .................................................................................................... 3
   CDC: Centers for Disease Control and Prevention | cdc.gov .......................................................... 3
   ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ............................. 4
   FDA: U.S. Food & Drug Administration | fda.gov ...................................................................... 5
   Public Health England | gov.uk ................................................................................................................ 5
   World Health Organization | who.int .................................................................................................... 5
Other relevant government bodies / health care organizations ............................................................... 5
   Center for Infectious Disease Research Policy .................................................................................. 6
   National Collaborating Centre for Environmental Health | ncceh.ca ................................................. 6
   Updated Daily ....................................................................................................................................... 6
   COVID-19 resources (case counts) | arcgis.com ............................................................................. 6
   COVID-19 Canada Open Data Working Group | COVID-19 CODWG ............................................ 6
   Johns Hopkins CCSE | systems.jhu.edu .................................................................................................. 6
   NextStrain| nextstrain.org .................................................................................................................... 6
Guidelines and Technical documents (updated weekly) ................................................................................. 7
Section I: General Guidelines .................................................................................................................. 7
   Ontario / Canada Main Page ............................................................................................................... 7
   Reopening/Rebuilding Guidelines ........................................................................................................ 7
### Vaccinations - General

- Compiled by PHO Library Services

### Vaccinations - Specific populations

- 13

### Vaccinations - Adverse Effects

- 15

### Background Information/Case Definitions

- 16

### Laboratories

- 16

### Miscellaneous Guidelines

- 18

### Data & Surveillance

- 19

### Variants – Omicron

- 20

### Testing

- 21

### Symptoms/Treatment

- 23

### COVID-19 Diagnosis in Children

- 24

### Post-COVID-19 Condition

- 25

### Case Investigation & Contact Tracing

- 26

### Infection Prevention and Control

- 26

### Section II: Guidelines for Health Sectors

- 27

#### Healthcare Providers

- 27

#### Congregate Living (including Long-Term Care, Prisons, and Shelters)

- 28

### Section III: Guidelines for the Community

- 29

#### Travel, Transport & Borders

- 29

#### Schools / Childcare

- 30

#### Mental Health /Addiction

- 30

#### Community

- 31

#### Businesses/Workplaces

- 32

#### Masks (Non-Medical)

- 32
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Key COVID updates [12-12-2022]
  - Weekly change in cases: 17,376
  - Total cases: 4,440,839
  - Weekly change in deaths: 243
  - Total deaths: 48,353
- NACI: updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration [12-09-2022]
  - NACI: Summary updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration [12-09-2022]
- COVID-19 daily epidemiology update [updated regularly]

BC Centre for Disease Control | bccdc.ca

- Clinical guidance on COVID-19 vaccines for persons with autoimmune rheumatic diseases [updated 12-05-2022]

Institut national de santé publique | inspq.qc.ca

- Pandémie et sentiment de sécurité personnelle - Résultats du 16 décembre 2022 [12-16-2022]
- Pandémie et vaccination - Résultats du 16 décembre 2022 [12-16-2022]
- Faits saillants du 16 décembre 2022 - Sondages sur les attitudes et comportements des adultes québécois [12-16-2022]

CDC: Centers for Disease Control and Prevention | cdc.gov

- Prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged 18 years who were hospitalized or died with influenza — United States, 2021–22 Influenza Season [12-15-2022]
Overall US COVID-19 vaccine distribution and administration update as of Wed, 14 Dec 2022 06:00:00 EST [12-14-2022]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- Communicable disease threats report, 11 – 17 December 2022, week 50 [12-16-2022]
- Country overview report: week 49 2022 [12-09-2022]
  - Long-term care facilities
    - At the end of week 49, 2022 (week ending 11 December), EU/EEA-level COVID-19 case rates increased by 6%, both in those aged 65 years and older and overall (all ages) compared to the previous week. At the EU/EEA-level, hospital occupancy has increased since the previous week, while hospital and ICU admissions and ICU occupancy indicators remain stable. Overall, the EU/EEA death rate also continued to decrease and is at low levels compared to the pandemic maximum. Given the current reversal of trends for some epidemiological indicators and the evolving variant scenarios, it remains important to continue monitoring the epidemiological situation.
    - The notification rates increased for all ages or for those aged 65 years and above in 23 countries, and the two indicators concurrently increased in 18 countries. In six countries, country-level rates among those aged 65 years and older surpass 30% of the respective country pandemic maximum.
    - Pooled EU/EEA hospital and ICU admissions have remained stable compared to the previous week. Nine countries reported an increase in at least one admission indicator since the previous week. Hospital occupancy at EU/EEA level has increased by 13%, whilst ICU occupancy has remained stable, with eight countries reporting increases in at least one occupancy indicator compared to the previous week. The decreasing trend in the pooled EU/EEA COVID-19 death rate is continuing, with five countries in the EU/EEA reporting increases over the past week.
    - Forecasts of cases and deaths from the European COVID-19 Forecast Hub provide predictions for weeks 50 and 51. Compared with the previous week, increasing trends in cases and stable trends in deaths are forecast for the EU/EEA overall by the end of week 51.
    - The cumulative uptake of a first booster was 65.3% (country range: 11.3–86.9%) among adults aged 18 years and older, 84.8% (country range: 13.3–100.0%) among individuals aged 60 years and older and 54.6% (country range: 9.2–75.7%) in the total population. The cumulative uptake of a second booster was 15.5% (country range: 0.1–41.4%) among adults aged 18 years and older, 33.1% (country range: 0.3–85.7%) among individuals aged 60 years and older and 12.7% (country range: 0.1–33.2%) in the total population.
    - Among the nine countries with an adequate volume of sequencing or genotyping for weeks 47–48 (21 November to 4 December 2022), the estimated distribution of variants of concern (VOC) or of interest (VOI) was 47.2% (18.9–93.7% from nine countries) for BA.5, 40.5% (25.3–69.4% from seven countries) for BQ.1, 8.0% (3.6–20.3% from nine countries) for BA.2.75, 5.5% (2.7–7.8% from four countries) for XBB, 0.9% (0.5–6.5%, 606 detections from nine countries) for BA.2 and 0.9% (0.5–2.6%, 336 detections from nine countries) for BA.4.

- Antiviral resistance monitoring capability and capacity for SARS-CoV-2 and influenza within the EU/EEA [12-15-2022]
- ECDC expert consultation on the implementation and evaluation of non-pharmaceutical interventions [12-14-2022]
- Data on COVID-19 vaccination in the EU/EEA [updated regularly]

**FDA: U.S. Food & Drug Administration | fda.gov**
- Coronavirus (COVID-19) update: daily roundup [updated regularly]
- FDA authorizes updated (bivalent) COVID-19 vaccines for children down to 6 months of age [12-08-2022]

**Public Health England | gov.uk**
**Note:** Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”
- Location of Public Health England (PHE) functions from 1 October 2021

**World Health Organization | who.int**
- WHO coronavirus (COVID-19) dashboard [updated regularly]

**Other relevant government bodies / health care organizations**
- Health Canada
  - Health professional risk communication: COMIRNATY original & Omicron BA.4/BA.5 bivalent vaccine with English-only vial and carton labels: new formulation for use in children 5 to less than 12 years of age [updated 12-09-2022]
- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]
- Statistics Canada
  - COVID-19: a data perspective [updated regularly]
  - Canadians’ awareness of when they have COVID-19, May to August 2022 [12-08-2022]
  - Provisional death counts and excess mortality, January 2020 to September 2022 [12-08-2022]
- UK Health Security Agency
- UK Department of Health and Social Care
  - Evaluation of medicines to prevent COVID-19 [updated 12-16-2022]
  - The COVID-19 Antivirals and Therapeutics Taskforce [updated 12-14-2022]
• UK Medicines and Healthcare products Regulatory Agency
  o Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine [updated 12-14-2022]
  o Regulatory approval of Spikevax (formerly COVID-19 Vaccine Moderna) [updated 12-14-2022]
  o Regulatory approval of COVID-19 Vaccine Janssen [updated 12-12-2022]
  o COVID-19 vaccines and medicines: updates for December 2022 [updated 12-12-2022]
  o Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 [updated 12-09-2022]

• UK Office for National Statistics

Center for Infectious Disease Research Policy | cidrap.umn.edu
• Parents more open to child’s COVID vaccination when given solid data [12-15-2022]
• More US teens hospitalized for mental illness during pandemic [12-15-2022]
• Study shows a third of Zambian corpses positive for COVID-19 [12-15-2022]
• Chinese citizens rush to hoard nonprescription [12-15-2022]
• Teens who receive routine vaccines more likely to get COVID shot [12-15-2022]

National Collaborating Centre for Environmental Health | ncceh.ca
• November research scan with COVID-19 sections [11-24-2022]
• October research scan with COVID-19 sections [10-20-2022]
• September research scan with COVID-19 sections [09-21-2022]

ProMED | promedmail.org
• Latest on COVID-19 [individual posts]
• COVID-19 update (189): mortality, mAb, intranasal vacc, NPIs, sequelae, WHO, global [12-08-2022]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
• Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
• COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
• 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
• Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
• Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
• Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
• Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 10-26-2022; posted 10-28-2022

Section I: General Guidelines

Ontario / Canada Main Page
• Ontario guidance
• Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
• ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
• CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
• CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
• BC B.C.'s response to COVID-19 [updated 10-12-2022]
• AB COVID-19 public health actions [no date]
• SK Living with COVID [no date]
• MB Manitoba Pandemic Response System [no date]
• QC Coronavirus disease (COVID-19) in Québec[08-17-2022]
• NB Living with COVID-19 [no date]
• NL Current Restrictions [no date]
• PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
• NS Reopening plan [updated regularly]
• NW COVID-19 [no date]
• YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
• NT Nunavut’s Path: Living with COVID-19 [no date]
• Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
• Implementation guidance for assessments of frontline service readiness [07-01-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

ECDC
• Data on country response measures to COVID-19 [updated 08-25-2022]
Transitioning beyond the acute phase of the COVID-19 pandemic: approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report [04-27-2022]

Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health

- COVID-19 vaccine-relevant information and planning resources [updated 10-17-2022]
- Ethical framework for COVID-19 vaccine distribution [archived] [updated 04-27-2022]

Canada (Federal)

- Updated guidance on COVID-19 vaccine booster doses in Canada [updated 10-07-2022]
- Archived 39: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines [updated 10-07-2022]
- COVID-19 drugs and vaccines [updated 09-16-2021]
- Planning guidance for immunization clinics for COVID-19 vaccines [09-22-2022]
- Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [06-29-2022]
- Summary of NACI statement of June 29, 2022 [06-29-2022]
- Adjusting public health measures in the context of COVID-19 vaccination [updated 06-27-2022]
- Health care provider vaccine tool kit. version 3 [06-10-2022]
- COVID-19 vaccine guide for youth and adults (12 years and over): Overview [08-11-2022]
- An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
- NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
- For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-22-2021]
- COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
- Planning guidance for administration of COVID-19 vaccine [12-21-2020]
- Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
- Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
- Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]
Provinces and territories (other than Ontario)

- BC Pfizer Pediatric Vaccine Shipping, Storage, Thawing and Use Guidelines (Orange/Maroon cap) [09-22-2022]
- BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 10-11-2022]
- BC COVID-19 vaccine eligibility [updated 10-11-2022]
- Spikevax™ (Moderna) [updated 10-11-2022]
- BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 09-14-2022]
- BC COVID-19 vaccine ChAdOx1-S [recombinant] [updated 09-14-2022]
- BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 09-14-2022]
- BC COVID-19 vaccine Ad26.COV2.S [recombinant] (Janssen) [updated 09-08-2022]
- BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [updated 10-11-2022]
- BC Pfizer redistribution guidelines [updated 07-20-2022]
- BC Immunization manual appendix A: informed consent (page 4) [updated 07-20-2022]
- BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [updated 07-20-2022]
- BC Moderna redistribution guidelines [updated 07-20-2022]
- BC Janssen shipping, storage and use guideline [updated 06-15-2022]
- BC Novavax shipping, storage and use guidelines [03-04-2022]
- BC Novavax redistribution guidelines [03-04-2022]
- BC Immunization manual: summary of changes: admin circular [03-04-2022]
- BC COVID-19 vaccine screening checklist [02-25-2022]
- BC Point of care risk assessment (PCRA) [no date]
- BC Janssen redistribution guidelines [01-17-2022]
- BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
- BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
- BC Administrative circular [12-31-2021]
- BC 2021/22 seasonal influenza vaccine eligibility [10-00-2021]
- BC Latex content in vaccines [10-00-2021]
- BC COVID-19 vaccination: why your 2nd dose is important [08-27-2021]
- BC Vaccine SOP: cold chain incident reporting process [updated 07-21-2021]
- BC Pfizer vaccine sub dose vial reporting [07-13-2021]
- BC COVID-19 Pfizer vaccine partial tray ULT distribution guidelines [05-19-2021]
- BC Cold chain assets warranty contact information [05-05-2021]
- BC Vaccine SOP: return of materials to manufacturers [04-30-2021]
• Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [08-18-2022]
• Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [06-06-2022]
• Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [06-06-2022]
• COVID-19 and mandatory vaccination: ethical considerations and caveats [05-30-2022]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.3 [04-21-2022]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination: addendum to policy brief, 5 April 2022 [04-05-2022]
• Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19v [03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [updated 03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
• Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: grading of evidence – evidence to recommendations tables [03-15-2022]
• Annexes to the interim recommendations for use of theChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [03-15-2022]
• Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
• Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
• Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
• NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
• COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
• Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination [11-05-2021]
• Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
• Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
• Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
• **Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19**: [06-01-2021]
• **Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief** [05-26-2021]
• **Health worker communication for COVID-19 vaccination flow diagram** [05-13-2021]
• **AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer** [05-10-2021]
• **AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine** [05-10-2021]
• **Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design** [05-07-2021]
• **COVID-19 exercise programme - drills for vaccine deployment** [05-03-2021]
• **Why are there extra doses of vaccine in the vaccine vial?** [04-16-2021]
• **Data for action: achieving high uptake of COVID-19 vaccines: interim guidance** [04-01-2021]
• **Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption** [11-01-2020]

**CDC**

• **COVID-19 vaccine boosters** [updated 10-24-2022]
• **Stay up to date with your COVID-19 vaccines** [updated 10-24-2022]
• **Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic** [updated 09-23-2022]
• **Understanding viral vector COVID-19 vaccines** [updated 09-16-2022]
• **COVID-19 vaccination program operational guidance** [updated 08-11-2022]
• **COVID-19 vaccine reporting systems** [updated 07-19-2022]
• **COVID-19 vaccination clinical & professional resources** [updated 05-13-2022]
• **Communication resources for COVID-19 vaccines** [12-11-2021]
• **Public health investigations of COVID-19 vaccine breakthrough cases: case investigations protocol** [no date]
• **Interim guidance for routine and influenza immunization services during the COVID-19 pandemic** [04-15-2021]
• **Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization** [04-14-2021]

**UK**

• **COVID-19 vaccination: information for healthcare practitioners** [10-10-2022]
• **COVID-19 vaccination: vaccine product information** [10-03-2022]
• **COVID-19 vaccination programme** [updated 09-07-2022]
• **COVID-19: the green book, chapter 14a** [updated 09-05-2022]
• **Monitoring reports of the effectiveness of COVID-19 vaccination** [09-01-2022]
• **National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant])** [04-01-2022]
• **National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine** [04-01-2022]
• National protocol for Spikevax (formerly COVID-19 vaccine Moderna) [04-01-2022]
• COVID-19 vaccination: blood clotting information for healthcare professionals [updated 02-14-2022]
• COVID-19 vaccination: booster dose resources [updated 02-02-2022]
• National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [11-20-2021]
• COVID-19 vaccination: what to expect after vaccination [updated 11-09-2021]
• Monitoring of the effectiveness of COVID-19 vaccination [09-14-2021]
• COVID-19: vaccine surveillance strategy [03-29-2021]

ECDC
• Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA. [updated 09-08-2022]
• COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 08-05-2022]
• Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines [07-11-2022]
• Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose [04-28-2022]
• Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update [03-14-2022]
• Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
• Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA [10-15-2021]
• Infographic: facilitating COVID-19 vaccination acceptance and uptake [10-15-2021]
• Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
• Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
• Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
• Countering online vaccine misinformation in the EU/EEA [06-29-2021]

Australia
• Clinical recommendations for COVID-19 vaccines [updated 10/24/2022]
• ATAGI recommendations on the use of a booster dose of COVID-19 vaccine [updated 10/24/2022]
• ATAGI clinical guidance for COVID-19 vaccine providers [updated 09-28-2022]
• COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination [08-31-2022]
• COVID-19 vaccination – vaccine dose policy [updated 07-13-2022]
• COVID-19 vaccination – updated provider kit for general practices [12-14-2021]
Vaccinations - Specific populations

Canada (Federal)

- An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age [10-21-2022]
- Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding [09-09-2022]
- Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview [modified 08-11-2022]
- Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [07-14-2022]
- Summary of NACI statement of July 14, 2022 [07-14-2022]
- NACI rapid response: guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [archived] [modified 06-29-2022]
- NACI rapid response: updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [archived] [modified 06-29-2022]
- NACI updated recommendations on the use of COVID-19 vaccines in children 6 months to 5 years of age [archived] [modified 03-17-2022]
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [modified 02-10-2022]
- Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]
- NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

- BC Health professionals COVID-19 vaccination status information and preventive measures – June 10, 2022 [06-10-2022]
- BC Residential care COVID-19 vaccination status [02-28-2022]

WHO
- Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-26-2021]
- Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
- Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC
- COVID-19 vaccines for children and teens [updated 10-24-2022]
- COVID-19 vaccines while pregnant or breastfeeding [updated 10-20-2022]
- COVID-19 vaccines for people who would like to have a baby [updated 07-14-2022]
- Resources to promote the COVID-19 vaccine for children & teens [09-13-2022]
- COVID-19 vaccine information for specific groups [06-19-2022]
- COVID-19 vaccine equity for racial and ethnic minority groups [03-29-2022]
- Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [01-20-2022]
- Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]
- Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]

UK
- COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [10-03-2022]
- COVID-19 vaccination: resources for children aged 5 to 11 years [03-28-2022]
- COVID-19 vaccination: resources for children and young people aged 12 to 17 years [02-01-2022]
- COVID-19 vaccination: guide for adults [01-19-2022]
- Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
- Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1 [02-18-2022]
- COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose [02-08-2022]
- Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]
Vaccinations - Adverse Effects

Canada (Federal)
- National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)
- BC Guidance document on the management of inadvertent vaccine errors [02-04-2022]
- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]

CDC
- Reported Adverse Events [updated 10-17-2022]
- COVID-19 vaccine side effects in children and teens [updated 09-14-2022]
- Possible side effects after getting a COVID-19 vaccine [updated 09-14-2022]
- Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [updated 09-02-2022]
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]

WHO
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- How to monitor and report COVID-19 vaccine side effects [03-15-2021]

UK
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [updated 10-07-2022]
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [03-21-2022]
- Myocarditis and pericarditis after COVID-19 vaccination [03-21-2022]
- COVID-19 vaccination: Guillain-Barré syndrome information for healthcare professionals [12-17-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Australia
- COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [09-23-2022]
Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [06-00-2022]

PHAC
- National case definition: coronavirus disease (COVID-19) [updated 10-03-2022]
- COVID-19 case report form [updated 09-09-2022]

CDC
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
- WHO COVID-19 Case definition [updated 07-22-2022]
- Revised case report form for confirmed Novel Coronavirus COVID-19 (report to WHO within 48 hours of case identification) [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]
- COVID-19: background information [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 10-14-2022]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15) [updated 08-31-2022]

PHAC
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [07-05-2022]
• **Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance** [04-12-2022]

• **Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing** [06-10-2021]

• **National polymerase chain reaction (PCR) testing indication guidance for COVID-19** [10-07-2020]

**WHO**

• **Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2** [03-30-2021]

• **Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19** [03-24-2022]

• **Laboratory biosafety guidance related to coronavirus disease (COVID-19)** [01-28-2021]

• **COVID-19 new variants: knowledge gaps and research** [01-12-2021]

• **Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health** [01-08-2021]

• **SARS-CoV-2 genomic sequencing for public health goals** [01-08-2021]

• **SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide** [12-21-2020]

• **Assessment tool for laboratories implementing SARS-CoV-2 testing** [10-23-2020]

• **Diagnostic testing for SARS-CoV-2: interim guidance** [09-11-2020]

• **Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays** [09-11-2020]

**CDC**

• **Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19** [updated 07-17-2022]

• **Testing strategies for SARS-CoV-2** [05-05-2022]

• **How to report COVID-19 laboratory data** [04-04-2022]

• **Guidance for SARS-CoV-2 point-of-care and rapid testing** [04-04-2022]

• **Guidance for reporting SARS-CoV-2 sequencing results** [03-21-2022]

• **Evaluation for SARS-CoV-2 testing in animals** [03-30-2022]

• **Guidance for general laboratory safety practices during the COVID-19 pandemic** [03-02-2022]

• **Using antibody tests for COVID-19** [02-24-2022]

• **Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings** [01-24-2022]

• **Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19)** [12-13-2021]

• **Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity** [10-29-2021]

• **Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination** [08-09-2021]

• **Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing** [06-30-2021]

• **Variants and genomic surveillance for SARS-CoV-2** [04-02-2021]

• **Resources for laboratories working on coronavirus (COVID-19)** [03-28-2021]
• Information for laboratories about coronavirus (COVID-19) [03-28-2021]

UK
• How tests and testing kits for coronavirus (COVID-19) work [10-07-2022]
• Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [07-11-2022]
• National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests [07-11-2022]
• Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [07-11-2022]
• Technical validation protocol for SARS-CoV-2 nucleic acid detection [07-11-2022]
• NHS test and trace statistics (England): methodology [05-18-2022]
• COVID-19: guidance for sampling and for diagnostic laboratories [03-29-2021]

ECDC
• The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates [05-10-2021]

Australia
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Miscellaneous Guidelines

PHAC
• Summary of evidence supporting COVID-19 public health measures [08-31-2022]
• Individual public health measures [updated 08-12-2022]
• COVID-19 and people with disabilities in Canada [07-06-2022]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]

Canadian provinces and territories (other than Ontario)
• BC COVID-19 ethical decision-making framework [12-24-2020]

WHO
• Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
• Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
• ACT-Accelerator 'fair share asks' - by country [02-09-2022]
• WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
• Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
• Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
• Critical preparedness, readiness and response actions for COVID-19: interim guidance [05-27-2021]

CDC
• Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [09-23-2022]
• Public health guidance for potential COVID-19 exposure associated with travel [updated 09-08-2022]
• Wildfire smoke and COVID-19 [08-02-2022]
• RRT composition: COVID-19 considerations [03-01-2021]

ECDC
• One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
• Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]

Other
• Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

Data & Surveillance
Canada
• COVID-19 data trends [modified 10-21-2022]
• Mathematical modelling and COVID-19 [modified 04-01-2022]
• National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO
• Public health surveillance for COVID-19: interim guidance [updated 07-22-2022]
• Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance [04-14-2022]
• WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [02-15-2022]
• End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance [01-31-2022]
• Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States [01-21-2022]

CDC
• Wastewater surveillance data reporting & analytics [updated 10-04-2022]
• National wastewater surveillance system (NWSS) [03-21-2022]
• Wastewater surveillance testing methods [01-26-2022]
• Public health interpretation and use of wastewater surveillance data [01-26-2022]
• Developing a wastewater surveillance sampling strategy [01-26-2022]
• Targeted wastewater surveillance at facilities, institutions, and workplaces [01-26-2022]
• **COVID-19 serology surveillance** [03-11-2021]
• **Data visualization** [02-16-2021]
• **Guide to global digital tools for COVID-19 response** [10-23-2020]
• **Large-scale geographic seroprevalence surveys** [10-02-2020]

**ECDC**

• **Organisation of vector surveillance and control in Europe** [12-13-2021]
• **Surveillance of COVID-19 in long-term care facilities in the EU/EEA** [11-29-2021]
• **Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30)** [11-29-2021]
• **COVID-19 variants: genomically confirmed case numbers** [11-29-2021]
• **Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA** [11-26-2021]
• **COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens** [10-18-2021]
• **Guidance for representative and targeted genomic SARS-CoV-2 monitoring** [05-03-2021]

**UK**

• **COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools** [09-04-2020]

**Variants – Omicron**

**Canada**

• **SARS-CoV-2 variants: national definitions, classifications and public health actions** [updated 08-18-2022]

**CDC**

• **Variants** [updated 08-11-2021]

**UK**

• **Investigation of SARS-CoV-2 variants: technical briefings** [updated 10-07-2022]
• **SARS-CoV-2 variants of public health interest** [updated 10-07-2022]

**ECDC**

• **Methods for the detection and characterisation of SARS-CoV-2 variants – first update** [updated 08-02-2022]
• **Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA** [06-13-2022]
• **Technical guidance for antigenic SARS-CoV-2 monitoring** [06-07-2022]
• **Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update** [01-27-2022]
• **Threat assessment brief: implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update** [12-02-2021]
• **Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00)** [11-30-2021]
• **Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA** [11-26-2021]

**WHO**
- **Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member stats** [updated 01-21-2022]

**Testing**

**Canada**
- **Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection** [07-07-2022]
- **Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan** [09-08-2021]
- **Guidance for repeated PCR testing in individuals previously positive for COVID-19** [12-08-2020]
- **National polymerase chain reaction (PCR) testing indication guidance for COVID-19** [10-07-2020]

**Ontario Ministry of Health**
- **COVID-19 provincial testing guidance. Version 15.2** [updated 10-06-2022]
- **Management of cases and contacts of COVID-19 in Ontario. Version 15** [08-31-2022]
- **COVID-19 test requisition** [06-12-2021]
- **Considerations for privately-initiated testing. version 3.0** [05-21-2021]
- **COVID-19 guidance: considerations for rapid antigen screening. Version 2.0** [02-17-2021]
- **Considerations for employer rapid antigen screening pilot** [11-20-2020]

**Canadian provinces and territories (other than Ontario)**
- **BC COVID-19: viral testing guidelines for British Columbia** [updated 09-28-2022]
- **BC COVID-19 infection prevention and control: guidance for test collection & assessment centres** [09-09-2021]
- **BC Infection prevention and control guidance for test collection and assessment centres** [09-09-2021]
- **BC Antibody testing (serology) page** [no date]

**WHO**
- **Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing** [03-09-2022]

**CDC**
- **Overview of testing for SARS-CoV-2 (COVID-19)** [updated 09-28-2022]
- **Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic** [updated 09-23-2022]
- **Testing strategies for SARS-CoV-2** [05-05-2022]
- **Guidance on prevention and management of coronavirus disease 2019 (COVID-19) in correctional and detention facilities** [05-03-2022]
- **Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community** [04-04-2022]
- **Guidance for SARS-CoV-2 point-of-care and rapid testing** [04-04-2022]
- **Using antibody tests for COVID-19** [02-24-2022]
- **CDC’s diagnostic test for COVID-19 only and supplies** [08-17-2021]
- **CDC diagnostic tests for covid-19** [08-07-2021]
- **Nucleic acid amplification tests (NAATs)** [06-14-2021]
• Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [06-14-2021]
• Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]
• Serology testing for COVID-19 at CDC [11-03-2020]

UK
• Investigation of SARS-CoV-2 variants: technical briefings [updated 10-07-2022]
• How tests and testing kits for coronavirus (COVID-19) work [updated 10-07-2022]
• SARS-CoV-2 variants of public health interest [updated 10-07-2022]
• Investigation of SARS-CoV-2 variants of concern: variant risk assessments [06-24-2022]
• SARS-CoV-2 variant of concern diagnostic assurance [04-14-2022]
• Testing for coronavirus (COVID-19) before hospital [03-08-2022]
• Coronavirus COVID-19 serology and viral detection tests: technical validation reports [updated 02-18-2022]
• Investigation of SARS-CoV-2 variants of concern: technical briefings [09-17-2021]
• Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021 [07-16-2021]
• Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021 [07-16-2021]
• SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence [10-16-2020]

ECDC
• Methods for the detection and identification of SARS-CoV-2 variants- first update [08-02-2022]
• A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control [04-27-2022]
• Assessment of point-of-care testing devices for infectious disease surveillance, prevention and control – a mapping exercise [04-27-2022]
• Considerations for the use of antibody tests for SARS-CoV-2 – first update [02-10-2022]
• Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories [12-20-2021]
• Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK [10-26-2021]
• Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings [05-06-2021]
• Considerations for the use of saliva as sample material for COVID-19 testing [05-03-2021]
• Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
• Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
• Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]
• Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
• COVID-19 testing strategies and objectives [09-18-2020]
• Objectives for COVID-19 testing in school settings [08-10-2020]
Australia

- PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [06-20-2022]
- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Symptoms/Treatment

Canada

- Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [06-22-2022]
- COVID-19 for health professionals: treatments [02-01-2022]
- Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health

- Management of cases and and contacts of COVID-19 in Ontario version 15 [updated 08-31-2022]
- COVID-19 patient screening guidance document version 5.0 [08-26-2021]

BC

- Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19 [updated 10-14-2022]
- Therapy in adult pregnant patients with COVID-19 [updated 09-07-2022]

WHO

- COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
- Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
- WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC

- Clinical Care Information for COVID-19 [updated 10-19-2022]
- Caring for post-COVID conditions [updated 09-01-2022]
• Ending home isolation for persons with COVID-19 not in healthcare settings [08-31-2022]
• Ending isolation and precautions for people with COVID-19: interim guidance [08-31-2022]
• If you are sick or caring for someone [08-11-2022]
• Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [06-15-2022]
• Clinical care quick reference for COVID-19 [03-16-2022]
• Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [08-31-2022]
• Standard operating procedure (SOP) for triage of suspected COVID-19 patients in non-US healthcare settings: early identification and prevention of transmission during triage [10-18-2021]
• Assessing risk factors for severe COVID-19 illness [11-30-2020]

WHO
• Therapeutics and COVID-19 [07-14-2022]
• COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate [02-04-2022]
• COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery [02-04-2022]
• COVID-19 clinical management: living guidance [11-23-2021]
• Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]
• Hypertension and COVID-19 [06-17-2021]
• WHO information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]
• Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
• WHO COVID-19 clinical care bundle [04-23-2021]
• Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance [08-13-2020]

US NIH
• COVID-19 treatment guidelines [updated 10-19-2022]

UK
• COVID-19: migrant health guide [03-08-2022]
• COVID-19: long-term health effects [updated 04-30-2021]

Australia
• Coronavirus (COVID-19) – identifying the symptoms [last updated 07-05-2022]
- COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C) [06-22-2022]

WHO

CDC
- Information for Pediatric Healthcare Providers [10-19-2022]
- Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]

Other
- BC Children with immune compromise [08-02-2022]
- American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [06-10-2022]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition

Canada
- Post COVID-19 condition (long COVID) [updated 10-20-2022]

Ontario
- Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2021]
- BC Living with persistent Post-COVID-19 symptoms
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [updated 10-22-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Post-COVID conditions: information for healthcare providers [updated 09-22-2021]
- Post-COVID conditions; CDC Science [09-02-2022]
- Caring for post-COVID conditions [09-01-2022]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- Long-term effects of coronavirus (long COVID) [08-09-2022]
Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [08-18-2022]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 15) [08-31-2022]

WHO
- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]

CDC
- Ending home isolation for persons with COVID-19 not in healthcare settings [08-31-2022]
- Quarantine and isolation [08-11-2022]
- Contact tracing resources for health departments [03-25-2022]
- Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
- Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2022]
- Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]
- Contact tracing for COVID-19 [02-10-2022]
- Investigating a COVID-19 case [01-21-2022]
- COVID-19 contact tracing communications toolkit for health departments [11-05-2021]
- Global contact tracing [01-15-2021]

UK
- COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [07-14-2022]
- People with symptoms of a respiratory infection including COVID-19 [06-10-2022]

Infection Prevention and Control

PHAC / Health Canada
- Coronavirus disease (COVID-19): prevention and risks [08-12-2022]
- COVID-19: Guidance on indoor ventilation during the pandemic [07-05-2022]
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]
Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health

- Management of cases and and contacts of COVID-19 in Ontario version 15 [08-31-2022]
- COVID-19 guidance: acute care v.8 [06-11-2022]
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]
Canada

- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

WHO

- COVID-19 home care bundle for health care workers [02-09-2022]
- Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]

CDC

- Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [09-23-2022]
- Staff shortages [09-23-2022]
- Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]

UK

- COVID-19: managing healthcare staff with symptoms of a respiratory infection [08-31-2022]

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- COVID-19 screening tool for long-term care homes and retirement homes: version 13 [08-31-2022]
- Ministry for seniors and accessibility COVID-19 guidance document for retirement homes in Ontario [06-24-2022]

PHAC

- COVID-19: guidance on pets and long-term care homes [07-20-2021]
- Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
- COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO

- Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC

- How to protect yourself and others [updated 10-19-2022]
Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health

- Travelling during COVID-19 [07-19-2022]
- Guidance for public transit agencies and passengers in response to COVID-19 [03-21-2022]

Canada

- Official global travel advisories [updated often]

CDC

- COVID-19 travel recommendations by destination [updated regularly]
- Stay up to date with your COVID-19 vaccines including Boosters [updated 10-24-2022]
- Requirement for proof of COVID-19 vaccination for air passengers [07-14-2022]
UK
- [COVID-19: guidance for people whose immune system means they are at higher risk](#) [updated 10-07-2022]
- [People with symptoms of a respiratory infection including COVID-19](#) [06-10-2022]
- [Coronavirus (COVID-19): advice for heavy goods (HGV) and public service vehicle (PSV) operators](#) [03-29-2022]
- [Coronavirus (COVID-19): cruise ship travel](#) [03-17-2022]

Schools / Childcare

Ontario Ministry of Health
- [Management of cases and contacts of COVID-19 in Ontario version 15](#) [08-31-2022]
- [COVID-19: health and safety measures for child care](#) [08-17-2022]
- [COVID-19: health and safety measures at schools](#) [08-15-2022]

PHAC
- [Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance](#) [07-22-2022]
- [Planning for the 2021-2022 school year in the context of COVID-19 vaccination](#) [02-10-2022]

CDC
- [Guidance for K-12 schools and childcare programs](#) [08-11-2022]
- [Schools, child care, and colleges](#) [08-11-2022]

UK
- [Emergency planning and response for education, childcare, and children's social care settings](#) [updated 10-03-2022]

Mental Health /Addiction

Ontario Ministry of Health
- [COVID-19 guidance: mental health and addictions service providers in community settings: version 2](#) [09-24-2020]

Provinces & Territories (excluding Ontario)
- QC [The roles of public health in population mental health and wellness promotion](#) [10-03-22]
- QC [Preventing loneliness in young adults in the context of a pandemic](#) [04-05-2022]
- BC [Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia](#) [07-00-2021]
- QC [Public health ethics and COVID-19: selected resources](#) [11-00-2021]
WHO
- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]
- Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19 [12-00-2021]
- Social isolation and loneliness among older people: advocacy brief [07-29-2021]
- Smoking and COVID-19 [06-30-2020]
- Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
- COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

SAMHSA
- Disaster planning handbook for behavioural health service programs [03-00-2021]
- Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [05-07-2020]
- Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK
- Alcohol and drug misuse prevention and treatment guidance [03-07-2022]
- Every Mind Matters: looking after your mental health [no date]
- Domestic abuse: how to get help [11-11-2021]

Community
Ontario Ministry of Health
- COVID-19 public health measures and advice [updated 10-12-2022]
- COVID-19 guidance: community emergency evacuations v.3 [05-16-2022]

PHAC
- Summary of evidence supporting COVID-19 public health measures [08-31-2022]
- Accessing public health support for First Nations communities [08-05-2022]
- COVID-19 and people with disabilities in Canada [07-06-2022]
- Reducing COVID-19 risk in community settings: a tool for operators [02-10-2022]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO
- WHO mass gathering COVID-19 risk assessment tool: generic events, version 3 [06-16-2022]

CDC
- Isolation and precautions for people with COVID-19 [08-11-2022]

UK
• Infection prevention and control in adult social care: COVID-19 supplement [updated 10-11-2022]
• Living safely with respiratory infections, including COVID-19 [06-16-2022]

Businesses/Workplaces
Ontario Ministry of Health
• COVID-19 public health measures and advice [no date]
• COVID-19 and workplace health and safety [09-14-2022]
• Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]
• Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization [11-30-2021]

WHO
• Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
• Specific settings [05-27-2022]
• Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

UK
• Reducing the spread of respiratory infections, including COVID-19, in the workplace [06-10-2022]

Masks (Non-Medical)
Ontario Ministry of Health
• Face coverings and face masks [09-07-2022]

PHAC
• COVID-19 mask use: advice for community settings [04-22-2022]

WHO
• Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline [03-07-2022]

CDC
• Your guide to masks [09-09-2022]

ECDC
• Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]

UK
• Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]
• The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]